From the Guidelines
Heart Failure Management with Jardiance (Empagliflozin)
Jardiance (Empagliflozin) is used in the management of heart failure to reduce the risk of cardiovascular death and hospitalization for heart failure. The following points highlight its use in heart failure:
- Jardiance is recommended for patients with heart failure with reduced ejection fraction (HFrEF) to reduce the risk of worsening heart failure and cardiovascular death 1.
- It has been shown to improve outcomes in patients with HFrEF by reducing blood pressure, decreasing cardiac preload and afterload, and improving cardiac function.
- Jardiance may also be beneficial in patients with heart failure with preserved ejection fraction (HFpEF), as demonstrated by the EMPEROR-Preserved trial, which showed a significant reduction in the primary composite endpoint of time to heart failure hospitalization or cardiovascular death 1.
Special Considerations
When using Jardiance in heart failure patients, the following special considerations should be taken into account:
- Monitoring of electrolyte levels and renal function is recommended, as Jardiance may increase the risk of hypotension, dehydration, and electrolyte imbalances 1.
- Jardiance may increase the risk of genital mycotic infections, urinary tract infections, and acute kidney injury, particularly in patients with pre-existing kidney disease or those taking other medications that affect kidney function.
- The benefit of Jardiance in heart failure patients is similar irrespective of the presence or absence of diabetes at baseline 1.
Potential Pitfalls
Potential pitfalls to consider when using Jardiance in heart failure patients include:
- Increased risk of euglycaemic diabetic ketoacidosis, particularly among patients with poor food intake 1.
- Increased risk of genitourinary infections, such as mycotic infections 1.
- Potential for adverse interactions with other medications that affect electrolyte balance or renal function.
From the FDA Drug Label
Indications for Jardiance (Empagliflozin)
Jardiance (Empagliflozin) is used in the following cases:
- To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure 2
- To reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression 2
Heart Failure Specifics
Jardiance is specifically indicated to reduce the risk of:
- Cardiovascular death
- Hospitalization for heart failure in adults with heart failure 2
From the Research
Heart Failure Management with Jardiance (Empagliflozin)
Jardiance (Empagliflozin) is used in the management of heart failure to reduce the risk of cardiovascular death and hospitalization for heart failure. The following points highlight its use in heart failure:
- Jardiance is recommended for patients with heart failure with reduced ejection fraction (HFrEF) to reduce the risk of worsening heart failure and cardiovascular death.
- It has been shown to improve outcomes in patients with HFrEF by reducing blood pressure, decreasing cardiac preload and afterload, and improving cardiac function.
- Jardiance may also be beneficial in patients with heart failure with preserved ejection fraction (HFpEF), as demonstrated by the EMPEROR-Preserved trial, which showed a significant reduction in the primary composite endpoint of time to heart failure hospitalization or cardiovascular death.
Special Considerations
When using Jardiance in heart failure patients, the following special considerations should be taken into account:
- Monitoring of electrolyte levels and renal function is recommended, as Jardiance may increase the risk of